Skip to content
Study details
Enrolling now

Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

Rachel Miller
NCT IDNCT03089554ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

93

Study length

about 9.1 years

Ages

18+

Locations

1 site in KY

About this study

Researchers are testing a treatment based on genomic analysis results to see if it helps people with cancer live longer. The trial will last for 3306 days and involve approximately 93 participants.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Therapeutic Intervention
PhasePhase 2
Primary goalProgression Free Survival

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Progression Free Survival

Body systems

Oncology